Review anchor
A549
CELL-LINE · Homo sapiens
As of 2026-09-13
Evidence Snapshot
A549
CHEMBL392
CELL-LINE
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats A549 as ChEMBL target CHEMBL392. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL392
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why A549 matters
A549 is reviewed as A549; the current evidence base includes 160 approved drugs, 103253 compounds, and 18154 assays, with lead potency reaching pChEMBL 10.9.
Protein context
A549
A549
Review this target as A549.
Protein source · UniProt accession via ChEMBL component mappingDisease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 160 approved drugs, 103253 compounds, and 18154 assays for this target. The dominant activity type is IC50. CHEMBL455213 is the current potency anchor at pChEMBL 10.9.
Use CHEMBL455213 as the tractability anchor when discussing potency (pChEMBL 10.9).
Activity source · ChEMBL 36 via Core Engine
160 approved
pChEMBL 10.9
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why A549 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
103253
Total Compounds
18154
Total Assays
160
Approved Drugs
IC50: 50871.0, EC50: 1245.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL455213
|
10.9 | IC50 | — |
|
|
No preferred name
CHEMBL1836551
|
10.8 | IC50 | — |
|
|
No preferred name
CHEMBL1836547
|
10.8 | IC50 | — |
|
|
No preferred name
CHEMBL2324626
|
10.7 | IC50 | — |
|
|
No preferred name
CHEMBL1836543
|
10.7 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
TIRBANIBULIN
CHEMBL571546
|
2020 |
|
|
SELUMETINIB
CHEMBL1614701
|
2020 |
|
|
FEDRATINIB
CHEMBL1287853
|
2019 |
|
|
DACOMITINIB ANHYDROUS
CHEMBL2110732
|
2018 |
|
|
PLITIDEPSIN
CHEMBL451930
|
2018 |
|
|
TIVOZANIB
CHEMBL1289494
|
2017 |
|
|
ABEMACICLIB
CHEMBL3301610
|
2017 |
|
|
BRIGATINIB
CHEMBL3545311
|
2017 |
|
|
OLMUTINIB
CHEMBL3786343
|
2016 |
|
|
PALBOCICLIB
CHEMBL189963
|
2015 |
|
|
PANOBINOSTAT
CHEMBL483254
|
2015 |
|
|
OSIMERTINIB
CHEMBL3353410
|
2015 |
|
|
CERITINIB
CHEMBL2403108
|
2014 |
|
|
IDELALISIB
CHEMBL2216870
|
2014 |
|
|
EMPAGLIFLOZIN
CHEMBL2107830
|
2014 |
|
|
BELINOSTAT
CHEMBL408513
|
2014 |
|
|
DABRAFENIB
CHEMBL2028663
|
2013 |
|
|
TRAMETINIB
CHEMBL2103875
|
2013 |
|
|
AFATINIB
CHEMBL1173655
|
2013 |
|
|
CABOZANTINIB
CHEMBL2105717
|
2012 |
|
|
TOFACITINIB
CHEMBL221959
|
2012 |
|
|
CRIZOTINIB
CHEMBL601719
|
2011 |
|
|
CABAZITAXEL
CHEMBL1201748
|
2010 |
|
|
ROMIDEPSIN
CHEMBL343448
|
2009 |
|
|
CARFILZOMIB
CHEMBL451887
|
2009 |
|
|
OMACETAXINE MEPESUCCINATE
CHEMBL46286
|
2009 |
|
|
VINFLUNINE
CHEMBL2110725
|
2009 |
|
|
TEMSIROLIMUS
CHEMBL1201182
|
2007 |
|
|
VORINOSTAT
CHEMBL98
|
2006 |
|
|
SORAFENIB
CHEMBL1336
|
2005 |
|
|
ERLOTINIB
CHEMBL553
|
2004 |
|
|
PEMETREXED
CHEMBL225072
|
2004 |
|
|
MYCOPHENOLIC ACID
CHEMBL866
|
2004 |
|
|
GEFITINIB
CHEMBL939
|
2003 |
|
|
TEMOPORFIN
CHEMBL500576
|
2001 |
|
|
EPIRUBICIN
CHEMBL417
|
1999 |
|
|
RALTITREXED
CHEMBL225071
|
1996 |
|
|
GEMCITABINE
CHEMBL888
|
1996 |
|
|
TOPOTECAN
CHEMBL84
|
1996 |
|
|
IRINOTECAN
CHEMBL481
|
1996 |
|
|
DOCETAXEL ANHYDROUS
CHEMBL92
|
1995 |
|
|
DOCETAXEL
CHEMBL3545252
|
1995 |
|
|
MYCOPHENOLATE MOFETIL
CHEMBL1456
|
1995 |
|
|
VINORELBINE TARTRATE
CHEMBL538943
|
1994 |
|
|
VINORELBINE
CHEMBL553025
|
1994 |
|
|
TRIMETREXATE
CHEMBL119
|
1993 |
|
|
TENIPOSIDE
CHEMBL452231
|
1992 |
|
|
PACLITAXEL
CHEMBL428647
|
1992 |
|
|
PODOFILOX
CHEMBL61
|
1990 |
|
|
MITOXANTRONE
CHEMBL58
|
1987 |
Source Header